Trial Profile

A multicenter, randomized, open label, clinical trial comparing a QD [once daily] regimen of didanosine, lamivudine and efavirenz with a standard BID [twice daily] regimen of zidovudine, lamivudine and efavirenz in the starting treatment of human immunodeficiency virus infection [GESIDA 39/03]

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Oct 2008 Final results have been reported in Clinical Infectious Diseases 47: 1083-1092, No. 8, 15 Oct 2008
16 Oct 2007 Biomarkers information updated
15 Oct 2007 Status changed from in progress to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com